Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Pool Corp (POOL) Q4 2025 Earnings Call Transcript (Fool) +++ POOL CORP Aktie +3,23%

CORCEPT THERAPEUTICS Aktie

 >Aktienkurs 
27.75 EUR    -17.9%    (TradegateBSX)
Ask: 27.81 EUR / 800 Stück
Bid: 27.62 EUR / 800 Stück
Tagesumsatz: 1176 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: -1,3%
1 Monat: +8,7%
3 Monate: -48,2%
6 Monate: -45,9%
1 Jahr: -52,2%
laufendes Jahr: -51,5%
>CORCEPT THERAPEUTICS Aktie
Name:  CORCEPT THERAPEUTICS INC.
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US2183521028 / 529882
Symbol/ Ticker:  HTD (Frankfurt) / CORT (NASDAQ)
Kürzel:  FRA:HTD, ETR:HTD, HTD:GR, NASDAQ:CORT
Index:  -
Webseite:  https://www.corcept.com/
Profil:  Corcept Therapeutics Incorporated is a pharmaceutical company specializing in the research, development, and commercialization of innovative therapies that modulate cortisol activity. With over 25 yea..
>Volltext..
Marktkapitalisierung:  3553.41 Mio. EUR
Unternehmenswert:  3198.94 Mio. EUR
Umsatz:  626.42 Mio. EUR
EBITDA:  57 Mio. EUR
Nettogewinn:  88.44 Mio. EUR
Gewinn je Aktie:  0.85 EUR
Schulden:  5.37 Mio. EUR
Liquide Mittel:  105.76 Mio. EUR
Operativer Cashflow:  137.63 Mio. EUR
Bargeldquote:  2.45
Umsatzwachstum:  11.88%
Gewinnwachstum:  -29.31%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 817.334 USD.
Suchwörter:  CORCEPT THERAPEUTICS, CORCEPT THERAPEUTIC
Letzte Datenerhebung:  19.02.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 105.19 Mio. St.
Frei handelbar: 88.12%
Rückkaufquote: 3.58%
Mitarbeiter: 500
Umsatz/Mitarb.: 1.14 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 110.76%
Bewertung:
KGV: 44.93
KGV lG: 41.17
KUV: 6.28
KBV: 6.54
PEG-Ratio: -
EV/EBITDA: 56.12
Rentabilität:
Bruttomarge: 98.19%
Gewinnmarge: 14.12%
Operative Marge: 8.85%
Managementeffizenz:
Gesamtkaprendite: 13.02%
Eigenkaprendite: 16.47%
>Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
19.02.26 - 17:24
Corcept Therapeutics: Aktie stürzt nach verlorener Patent-Berufung ab (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
17.02.26 - 22:09
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
 
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept...
13.02.26 - 00:57
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT (PR Newswire)
 
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.......
09.02.26 - 14:15
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm (PR Newswire)
 
SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant – came on January 30, 2026 when Reuters reported that......
09.02.26 - 10:57
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
 
LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation......
09.02.26 - 09:42
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of the securities......
06.02.26 - 03:02
Insiderhandel: Chief Development Officer verkauft Aktien von Corcept Therapeutics im Wert von 817334 USD (Insiderkauf)
 
Guyer, William - Vorstand - Tag der Transaktion: 2026-02-03...
05.02.26 - 11:24
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, Feb. 5, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of the securities......
05.02.26 - 10:51
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
 
LOS ANGELES, Feb. 5, 2026 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation......
02.02.26 - 23:48
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm (PR Newswire)
 
SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant – came on January 30, 2026 when Reuters reported that......
02.02.26 - 10:45
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
 
LOS ANGELES, Feb. 2, 2026 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation......
02.02.26 - 10:45
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, Feb. 2, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of the securities......
29.01.26 - 10:33
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, Jan. 29, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of the securities......
29.01.26 - 10:33
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
 
LOS ANGELES, Jan. 29, 2026 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation......
22.01.26 - 14:24
Corcept Therapeutics: Aktie schießt nach Studienerfolg bei Krebsmedikament um 45 % hoch (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
22.01.26 - 00:39
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm (PR Newswire)
 
SAN FRANCISCO, Jan. 21, 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL") from the FDA for its proposed treatment of......
15.01.26 - 16:06
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT (PR Newswire)
 
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.......
15.01.26 - 12:48
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit (24/7 Wall St.)
 
Corcept Therapeutics (NASDAQ: CORT) and Amicus Therapeutics (NASDAQ: FOLD) delivered Q3 2025 results highlighting two rare disease biotechs at opposite ends of the profitability spectrum. Corcept posted revenue of $207.6 million, up 13.7% year-over-year, with net income of $19.4 million. Amicus reported revenue of $169.1 million, up 19.5%, while turning a quarterly profit of $17.3 ... One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit The post One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit appeared first on 24/7 Wall St.....
15.01.26 - 07:33
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, Jan. 15, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of the securities......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die meisten großen Politiker haben ein System wie alle großen Philosophen, das ihre Lebensführung gestimmt und sie beständig dem gleichen Ziel zustreben läßt. - Luc de Clapiers Vauvenargues
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!